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For the successful implementation of Distributed Drug Discovery (D
3) (outlined in the accompanying
Perspective), students, in the course of their educational laboratories, must be able to reproducibly make
new, high quality, molecules with potential for biological activity. This article reports the successful
achievement of this goal. Using previously rehearsed alkylating agents, students in a second semester organic
chemistry laboratory performed a solid-phase combinatorial chemistry experiment in which they made 38
new analogs of the most potent member of a class of antimelanoma compounds. All compounds were made
in duplicate, puriﬁed by silica gel chromatography, and characterized by NMR and LC/MS. As a continuing
part of the Distributed Drug Discovery program, a virtual D
3 catalog based on this work was then enumerated
and is made freely available to the global scientiﬁc community.
Introduction
Three key components of the chemistry phase of Distrib-
uted Drug Discovery (D
3)
1 are reagent rehearsal,
2 virtual
library enumeration, and targeted library synthesis. In the
rehearsal laboratories, diversity reagents are evaluated in
duplicate for potential use at each step of a distributed drug
discovery combinatorial synthesis. Virtual D
3 catalogs are
then generated using only those diversity reagents that
perform satisfactorily or whose potential is well-precedented
from the literature. Computational analysis of these catalogs
leads to a “targeted” library subset, which students then
synthesize in a distributed fashion.
Our ﬁrst virtual D
3 catalog was reported in the previous
paper.
2 It is now freely available to the global community
for analysis by computational models appropriate for ne-
glected diseases. While waiting for molecular targets to
emerge from this process, a disease and class of target
molecules was identiﬁed that would allow testing the
capability of D
3 methodologies to make new, high-quality,
potentially biologically active molecules. In 2005 researchers
at the University of Illinois reported the discovery, from a
combinatorial library, of molecules that induced apoptosis
in a melanoma cell line.
3-5 The most potent molecule (IC50
) 0.5 µM) in their collection was 1 (from the R-isomer of
phenylalanine). A close analog, 2, also showed signiﬁcant
activity (Figure 1).
We had already demonstrated a distributed drug discovery
synthesis procedure that can provide, from alkylating agents
R1X and acylating agents R2COCl, acylated unnatural amino
acids of general structure 7 (original route, Scheme 1).
2,6
The four-step sequence involves the alkylation of resin-bound
glycinate (3 f 4), followed by imine hydrolysis (4 f 5),
N-acylation (5 f 6), and ﬁnal cleavage from the resin (6 f
7). It was apparent that modiﬁcation of this procedure
(modiﬁed route, Scheme 1) could produce numerous phe-
nylalanine methyl ester analogs, 8,o f1 and 2.
In Part I, we report using this adaptation to perform the
ﬁrst successful demonstration of targeted D
3 synthesis. In
Part II, we enumerate, for open-access analysis, an ac-
companying virtual D
3 catalog of acylated unnatural amino
acid methyl esters.
Results and Discussion
Part I. Development and Implementation of a D
3
Synthetic Process Providing Analogs of Anti-Melanoma
Compounds. The synthesis of 6 was carried out as previ-
ously reported.
2 Cleavage of 6 to 8 by transesteriﬁcation with
methanol in triethylamine at 55 °C for 48 h proceeded
smoothly and with good conversion. In the student labora-
tory, this modiﬁed route to compounds 8 proceeded unevent-
* To whom correspondence should be addressed. E-mail: wscott@
iupui.edu.
† Indiana University-Purdue University Indianapolis.
# Eli Lilly and Company.
Figure 1. Compounds inducing apoptosis in a melanoma cell
line.
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Published on Web 12/23/2008fully. In addition to the two known compounds 8a and 8b,
38 new compounds were prepared in duplicate. A single
student puriﬁed each compound to afford characterized
products in high purity. The results for the alkylating agents
used and the products formed are shown in Table 1.
As predicted from the database of alkylating agents
reported in the previous paper in this Journal,
2 the desired
molecules were obtained in all cases, even with the prob-
lematic methoxy-substituted benzene derivatives 8{23}a,b,
8{24}a,b, and 8{25}a,b. Each product from this laboratory
was subsequently puriﬁed by manual silica gel chromatog-
raphy, six compounds at a time, using a Bill-Board
1,8 setup
modiﬁed for puriﬁcation rather than synthesis. The ﬁnal
products were, on average, >95% pure by LC/MS. Sufﬁcient
material was obtained to provide product for testing, with
an average isolated chemical yield of 48% for the four-step,
50 µmol reaction sequence (see Experimental Section). The
puriﬁed samples were fully characterized by NMR. Figure
2 shows crude and puriﬁed product for a representative case
where the crude purity was close to the average for all
the samples.
Part II. Virtual D
3 Catalog Enumeration of Acylated
Unnatural Amino Acid Methyl Esters for Open-Access
Availability. An essential component of Distributed Drug
Discovery is the open-access availability of databases of
molecules accessible through distributed chemistry.
1 Com-
putational chemists can analyze these large databases to
identify and make globally available smaller databases of
potential drug leads targeted for developing world diseases.
Subsequently, the synthesis of the selected molecules will
be carried out, in a distributed fashion, at sites across the
world. As new D
3 compatible synthetic procedures are
developed, accompanying virtual D
3 catalogs will be enu-
merated for open-access retrieval and searching. Since the
present work demonstrates the D
3 route to acylated unnatural
amino acid methyl esters, a new virtual D
3 catalog based on
this chemistry was created. The compounds (including
stereoisomers when appropriate) in this virtual D
3 catalog
were enumerated with commercial software.
9 The complete
virtual D
3 catalog is freely available online through the
Collaborative Drug Discovery interface.
10 Utilizing the same
electrophiles and carboxylic acids (and rationale for selection)
as in our previous synthesis of acylated unnatural amino
acids,
2 24 192 acylated unnatural amino acid methyl esters
were enumerated.
As in the previous enumeration, this 24 192-member
virtual catalog contains more than the 10 000 members that
would arise from a simple 100 × 100 combinatorial process.
This is because the alkylation step provides racemic products,
and the acylation step can lead to additional stereoisomers,
each of which is listed separately. This allows appropriate
computational discrimination and selection when three-
dimensional molecular modeling software is employed and
chirality is important. See the earlier article for a more
complete discussion of these stereochemical issues.
2 The
compound structures in the virtual catalog were further
adjusted to take into consideration possible transformations
in the ﬁnal methanolysis step
11-16 (e.g., transesteriﬁcation
of ethyl esters to methyl esters).
Summary and Conclusion
This laboratory exercise demonstrates the ability to carry
out a critical component of Distributed Drug Discovery: the
targeted, replicated synthesis, by students in their normal
undergraduate laboratory, of new molecules selected from a
large virtual catalog of molecules accessible from student-
rehearsed diversity reagents. Because these reagents had been
previously rehearsed globally in Indianapolis, Barcelona,
Lublin and Moscow, D
3 correctly predicted every combi-
natorial synthesis would work. All the desired analogs were
successfully made and puriﬁed. A 24 192-member virtual
Scheme 1. General Route to Analogs 8 of Anti-Melanoma Compounds
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3 catalog based on this chemistry was enumerated and is
available through open-access.
Experimental Section
General Methods. All resins were purchased from
Polymer Laboratories, and all reactions and washes were
conducted at ambient temperature unless otherwise noted.
Organic solvents were of reagent grade and were used
directly without puriﬁcation. Anhydrous N-methylpyrrolidi-
none (NMP), chloroform-d1, 2-ﬂuorobenzyl bromide, 4-ﬂuo-
robenzyl bromide, 2-(triﬂuoromethyl)benzyl bromide, 4-(tri-
ﬂuoromethyl)benzyl bromide, 2-bromobenzyl bromide,
2-methoxybenzyl chloride, and 4-methylbenzyl bromide were
purchased from Acros Organics. Triﬂuoroacetic acid (TFA)
Table 1. Alkylating Agents Used and Products Synthesized
a
a Crude LC/MS purities. Asterisk (*) represents the puriﬁed product. Superscript one indicates isolated, overall puriﬁed yields for four step synthesis
to a and b, respectively, and superscript two indicates a result that is greater than the theoretical result based on presumed resin loading (see ref 7).
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BTPP (tert-butyl-imino-tri(pyrrolidino)phosphorane)
17 and
Fmoc chloride were purchased from Fluka. N,N-Diisopro-
pylethylamine (DIEA), benzyl bromide, 3-ﬂuorobenzyl chlo-
ride, 3-(triﬂuoromethyl)benzyl chloride, 3-bromobenzyl bro-
mide, 4-bromobenzyl bromide, 3-(bromomethyl)benzonitrile,
4-(bromomethyl)benzonitrile, 2-iodobenzyl bromide, 4-io-
dobenzyl bromide, 3-methoxybenzyl chloride, 4-methoxy-
benzyl chloride, 1-(chloromethyl)naphthalene, 2-(bromom-
ethyl)naphthalene, and methanol-d4 were obtained from
Aldrich Chemical Co.
Manual solid-phase organic syntheses at ambient tem-
perature were carried out in 3.5 mL fritted glass reaction
vessels equipped with polypropylene screw caps with
Teﬂon faced silicon septa on the Bill-Board set, which
was designed by one of us (WLS) as inexpensive
equipment
8 to simplify and expedite multiple, manual
solid-phase syntheses. This set is available from Leads
Metal Products Inc. (larry@leadsmetal.com). The Bill-
Board reaction vessel components are available from
ChemGlass: IUP-0305-270H for 3.5 mL reaction vessel;
IUP-0305-280H (polypropylene screw cap); IUP-0305-
281H (Teﬂon faced silicone septa).
Analytical thin layer chromatography (TLC) was per-
formed with Merck silica gel 60 F254, 0.25 mm precoated
glass plates. TLC plates were visualized using UV254. Flash
column chromatography was performed on silica gel 60
(230-400 mesh) from Silicycle Chemical Division. The
yields of the ﬁnal compounds, after chromatographic puri-
ﬁcation, were calculated on the basis of the initial loading
of the starting resins and are the overall yields of all reaction
steps starting from these resins.
1H NMR spectra were recorded at 200 MHz (Varian
spectrometer) in chloroform-d1 and methanol-d4 (3-10%),
with TMS as standard. Electrospray ionization mass spec-
trometry was conducted using a PESciex API III triple-stage
quadrupole mass spectrometer operated in either positive-
ion or negative-ion detection mode.
The composition of crude reaction mixtures was deter-
mined based on the integration of NMR spectra, as well as
LC-MS results. LC-MS analyses were conducted using an
Agilent system, consisting of a 1100 series HPLC connected
to a diode array detector and a 1946D mass spectrometer
conﬁgured for positive-ion/negative-ion electrospray ioniza-
tion. The LC-MS samples were analyzed as solutions in
CH3CN, prepared at 0.08-0.12 mg/mL concentration. The
composition of mixtures was determined by LC-MS based
on UV integration at 210 nm.
General Procedures for Manual Solid-Phase Organic
Synthesis. (a) Alkylation (3 to 4). Resin 3 was distributed
by volume as aliquots from an isopycnic suspension. The
Bill-Boards (19, one for each student in the laboratory, a
total of 114 reactions) were placed in their drain trays and,
from a neutral buoyancy suspension in dichloromethane
(DCM)/NMP, 50 µmols of the benzophenone imine of
glycine Wang resin (3, resin loading ) 0.7 mmol/g) was
distributed, via repeated 1 mL aliquots, to each of the 6
reaction vessels in a given Bill-Board 6-pack. During the
distribution of the resin, the isopycnic solvent was allowed
to drain through the frit in the reaction vessels. When
distribution was complete, residual solvent was removed with
an “air-push” from a disposable plastic pipet ﬁtted with a
pierced septum that could be placed over the open mouth of
the reaction vessel. The resin was then washed with NMP
(3 × 3 mL).
The bottom of each reaction vessel was capped and a new
calibrated disposable plastic pipet was used for each alky-
lating agent. The ﬁrst
1R1-X (benzyl bromide) [0.5 mL of a
0.20 M solution in NMP, 100 µmols, 2 equiv] was added to
the resin in the two reaction vessels in the ﬁrst column
positions (i.e., A1 and B1). Then the second
2R1-X [0.5 mL
of a 0.20 M solution in NMP, 100 µmols, 2 equiv] was added
Figure 2. Representative analytical results for the crude and puriﬁed analog 8{15}a.
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(i.e., A2 and B2). Finally, the third
3R1-X [0.5 mL of a 0.20
M solution in NMP, 100 µmols, 2 equiv] was added to the
resin in the two vessels in the third column positions (i.e.,
A3 and B3). Base was then added [0.5 mL of a 0.20 M
solution of BTPP in NMP, 100 µmols, 2 equiv] to each of
the six reaction vessels. The tops of all reaction vessels were
capped and the Bill-Board was placed in a rotation apparatus.
The alkylation reaction was allowed to proceed for two days
with rotation.
18
(b) Hydrolysis (4 to 5). The Bill-Board was removed from
the rotation apparatus and, after inverting the board, the
bottom caps were removed. The Board was then placed, top
side up, in the drain tray; the top caps were removed, and
the reagents from the alkylation step were allowed to drain,
followed by an air-push. The resin-bound alkylated products
4 were washed with THF (1 × 3 mL). Using 6 clean caps,
the bottom of each reaction vessel was capped, anda1N
aqueous HCl-THF solution (1:2, 2.5 mL) was added to each
of the six reaction vessels. The caps were then put on the
top of each vessel, and the Bill-Board was returned to the
rotator for 20 min. The reagents and byproduct from the
hydrolysis were then removed from hydrolyzed resin-bound
product (5) by ﬁltration and washing with THF (1 × 3 mL)
and then NMP (1 × 3 mL).
(c) Acylation (5 to 6). Using clean caps, the bottom of
each reaction vessel was capped, and the ﬁrst acylating agent,
triphenylacetyl chloride [0.5 mL of a 0.30 M solution of
R2COCl in NMP, 150 µmols, 3 equiv] was added to the resin
5 in each of the three vessels in row A (A1, A2, and A3).
Then the second acylating agent, triphenylpropionyl chloride
[0.5 mL of a 0.30 M solution of R2COCl in NMP, 150 µmols,
3 equiv] was added to the resin 5 in each of the three vessels
in row B (B1, B2, and B3). This was followed by addition
of DIEA [0.5 mL of a 0.60 M solution in NMP, 300 µmols,
6 equiv] to each of the six reaction vessels. The tops of the
reaction vessels were capped and the reaction was allowed
to proceed with rotation for 30 min.
(d) Cleavage of Products from Resin (6 to 8). The Bill-
Board was removed from the rotation apparatus, followed
by the usual ﬁltration/washing procedure. Acylated resin-
bound product 6 was washed with NMP (2 × 3 mL), CH2Cl2
(2 × 3 mL), THF (2 × 3 mL), and MeOH (2 × 3 mL). The
bottom of each reaction vessel was capped with a clean cap
and Et3N/MeOH (3:7, 2.5 mL) was added to each vessel.
After securely capping the top of each reaction vessel with
a clean cap, the reaction vessels were placed in an oven for
two days at 55 °C. The products 8 were then collected in
tared tool-necked vials. An air-push apparatus was used to
ﬁnish draining the reaction vessels. The resin was rinsed with
THF (1 × 2 mL), and this rinse was also collected. After
each collection vial was swirled to thoroughly mix the
cleavage and rinse solutions, a sample of each solution (100
µL) containing product 8 was transferred to an autosampler
vial for LC/MS analysis. The cleavage solvent and rinses
were evaporated with a simple, inexpensive apparatus
designed to speed up the evaporation with a stream of
nitrogen.
Puriﬁcation of Products. One student puriﬁed all the
products from this laboratory. To enable an efﬁcient selection
of gradient conditions, the products were gathered in groups
of 6 according to retention times from the LC/MS data. The
puriﬁcations were done six at a time, using a modiﬁed Bill-
Board in which the reaction vessel plate was suspended
above the collection vial rack and silica gel cartridges (6 ×
3 mL/500 mg, Fisher Cat. No. 11-131-1) replaced the
reaction vessels.
a Series: 8, R2 ) N-(Triphenylacetyl). Methyl N-
(Triphenylacetyl)phenylalaninate [8{9}a]: 16.7 mg (74%
isolated yield) following chromatographic puriﬁcation (EtOAc/
hexanes, 15:85); initial LC/MS purity 100%, tR ) 6.01 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.92 (dd, J )
14.0 Hz, J ) 7.6 Hz, 1H), 3.13 (dd, J ) 14.2 Hz, J ) 5.2
Hz, 1H), 3.71 (s, 3H), 4.90 - 5.00 (m, 1H), 6.17 (d, J ) 7.2
Hz, 1H), 7.11 - 7.25 (m, 20H); LC/MS calcd for C30H27NO3
[M + H]
+ 450.2; found 450.2.
Methyl 2-Fluoro-N-(triphenylacetyl)phenylalaninate
[8{10}a]: 10.6 mg (45% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 8:92 to 15:85); initial
LC/MS purity 77%, tR ) 5.99 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.01 (dd, J ) 14.1 Hz, J ) 8.1 Hz,
1H), 3.15 (dd, J ) 13.9 Hz, J ) 5.5 Hz, 1H), 3.72 (s, 3H),
4.87-4.97 (m, 1H), 6.28 (d, J ) 7.4 Hz, 1H), 6.90-7.02
(m, 4H), 7.03-7.25 (m, 15H); LC/MS calcd for C30H26FNO3
[M + H]
+ 468.2; found 468.2.
Methyl 3-Fluoro-N-(triphenylacetyl)phenylalaninate
[8{11}a]: 9.2 mg (39% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 8:92 to 15:85); initial
LC/MS purity 52%, tR ) 6.00 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 2.93 (dd, J ) 14.1 Hz, J ) 7.5 Hz,
1H), 3.12 (dd, J ) 14.2 Hz, J ) 5.2 Hz, 1H), 3.72 (s, 3H),
4.90-5.02 (m, 1H), 6.16 (d, J ) 7.1 Hz, 1H), 6.58-6.95
(m, 4H), 7.09-7.30 (m, 15H); LC/MS calcd for C30H26FNO3
[M + H]
+ 468.2; found 468.2.
Methyl 4-Fluoro-N-(triphenylacetyl)phenylalaninate
[8{12}a]: 25.6 mg (110% isolated yield
7) following chro-
matographic puriﬁcation (EtOAc/hexanes, 8:92 to 15:85);
initial LC/MS purity 85%, tR ) 6.01 min;
1H NMR (200
MHz, 10% CD3OD/CDCl3) δ 2.91 (dd, J ) 14.1 Hz, J )
7.5 Hz, 1H), 3.09 (dd, J ) 14.1 Hz, J ) 5.3 Hz, 1H), 3.71
(s, 3H), 4.89-4.99 (m, 1H), 6.17 (d, J ) 7.6 Hz, 1H),
6.78-6.97 (m, 4H), 7.08-7.30 (m, 15H); LC/MS calcd for
C30H26FNO3 [M + H]
+ 468.2; found 468.2.
Methyl 2-(Triﬂuoromethyl)-N-(triphenylacetyl)pheny-
lalaninate [8{13}a]: 9.3 mg (36% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 15:85); initial
LC/MS purity 94%, tR ) 6.21 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.01 (m, 1H), 3.30 (dd, J ) 15.0
Hz, J ) 5.4 Hz, 1H), 3.72 (s, 3H), 4.96-5.08 (m, 1H), 6.21
(d, J ) 7.8 Hz, 1H), 7.04-7.06 (m, 18H), 7.61 (d, J ) 7.8
Hz, 1H); LC/MS calcd for C31H26F3NO3 [M + H]
+ 518.2;
found 518.2.
Methyl 3-(Triﬂuoromethyl)-N-(triphenylacetyl)pheny-
lalaninate [8{14}a]: 8.9 mg (34% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 15:85); initial
LC/MS purity 49%, tR ) 6.24 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.02 (dd, J ) 14.1 Hz, J ) 7.3 Hz,
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4.99 (dd, J ) 12.7 Hz, J ) 7.3 Hz, 1H), 6.21 (d, J ) 7.0
Hz, 1H), 7.09 - 7.35 (m, 18H), 7.49 (d, J ) 7.6 Hz, 1H);
LC/MS calcd for C31H26F3NO3 [M + H]
+ 518.2; found
518.2.
Methyl 4-(Triﬂuoromethyl)-N-(triphenylacetyl)pheny-
lalaninate [8{15}a]: 12.7 mg (49% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 15:85); initial
LC/MS purity 81%, tR ) 6.28 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.00 (dd, J ) 14.2 Hz, J ) 7.2 Hz,
1H), 3.20 (dd, J ) 14.1 Hz, J ) 5.3 Hz, 1H), 3.72 (s, 3H),
4.94-5.05 (m, 1H), 6.16 (d, J ) 7.4 Hz, 1H), 7.02 (d, J )
8.0 Hz, 2H), 7.12-7.26 (m, 15H), 7.44 (d, J ) 8.0 Hz, 2H);
LC/MS calcd for C31H26F3NO3 [M + H]
+ 518.2; found
518.2.
Methyl 2-Bromo-N-(triphenylacetyl)phenylalaninate
[8{16}a]: 3.6 mg (14% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 98%, tR ) 6.20 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 3.05 (dd, J ) 13.9 Hz, J ) 9.9 Hz, 1H),
3.28 (dd, J ) 14.2 Hz, J ) 5.4 Hz, 1H), 3.73 (s, 3H),
4.91-5.03 (m, 1H), 6.34 (d, J ) 7.8 Hz, 1H), 7.04-7.26
(m,18H), 7.49 (d, J ) 4.5 Hz, 1H); LC/MS calcd for
C31H26BrNO3 [M + H]
+ 528.1; found 528.1.
Methyl 3-Bromo-N-(triphenylacetyl)phenylalaninate
[8{17}a]: 16.2 mg (62% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 81%, tR ) 6.26 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.89 (dd, J ) 13.9 Hz, J ) 7.7 Hz, 1H),
3.13 (dd, J ) 14.1 Hz, J ) 5.3 Hz, 1H), 3.72 (s, 3H),
4.88-4.99 (m, 1H), 6.17 (d, J ) 7.4 Hz, 1H), 6.85 (d, J )
7.6 Hz, 1H), 7.02-7.38 (m,18H); LC/MS calcd for
C31H26BrNO3 [M + H]
+ 528.1; found 528.1.
Methyl 4-Bromo-N-(triphenylacetyl)phenylalaninate
[8{18}a]: 18.5 mg (70% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 84%, tR ) 6.30 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.89 (dd, J ) 14 Hz, J ) 7.8 Hz, 1H),
3.08 (dd, J ) 14.2 Hz, J ) 5.4 Hz, 1H), 3.71 (s, 3H), 4.94
(dd, J ) 12.9 Hz, J ) 7.6 Hz, 1H), 6.14 (d, J ) 7.2 Hz,
1H), 6.76 (d, J ) 8.2 Hz, 2H), 7.12-7.32 (m, 17H); LC/
MS calcd for C30H26BrNO3 [M + H]
+ 528.1; found 528.1.
Methyl 3-Cyano-N-(triphenylacetyl)phenylalaninate
[8{19}a]: 14.0 mg (59% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/CH2Cl2, 20:80); initial LC/MS
purity 77%, tR ) 5.66 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.99 (dd, J ) 14.2 Hz, J ) 7.4 Hz, 1H),
3.16 (dd, J ) 14 Hz, J ) 5.2 Hz, 1H), 3.72 (s, 3H), 4.99
(dd, J ) 12.0 Hz, J ) 7.2 Hz, 1H), 6.19 (d, J ) 7.6 Hz,
1H), 7.14-7.35 (m, 18H), 7.52 (d, J ) 7.6 Hz, 1H); LC/
MS calcd for C31H26N2O3 [M + H]
+ 475.2; found 475.2.
Methyl 4-Cyano-N-(triphenylacetyl)phenylalaninate
[8{20}a]: 17.9 mg (76% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/CH2Cl2, 20:80); initial LC/MS
purity 75%, tR ) 5.66 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 3.02 (dd, J ) 14.1 Hz, J ) 7.3 Hz, 1H),
3.19 (dd, J ) 13.9 Hz, J ) 5.3 Hz, 1H), 3.72 (s, 3H), 5.01
(dd, J ) 14.0 Hz, J ) 7.2 Hz, 1H), 6.20 (d, J ) 7.6 Hz,
1H), 7.02 (d, J ) 8.2 Hz, 2H), 7.15-7.28 (m, 15H), 7.47
(d, J ) 8.4 Hz, 2H); LC/MS calcd for C31H26N2O3 [M +
H]
+ 475.2; found 475.2.
Methyl 2-Iodo-N-(triphenylacetyl)phenylalaninate [8-
{21}a]: 17.3 mg (60% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 84%, tR ) 6.27 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.95-3.10 (m, 1H), 3.29 (dd, J ) 14.2
Hz, J ) 7.4 Hz, 1H), 3.74 (s, 3H), 4.93 (m, 1H), 6.32 (d, J
) 7.6 Hz, 1H), 6.91-7.25 (m, 18H), 7.79 (d, J ) 7.0 Hz,
1H); LC/MS calcd for C30H26INO3 [M + H]
+ 576.1; found
576.1.
Methyl 4-Iodo-N-(triphenylacetyl)phenylalaninate [8-
{22}a]: 15.9 mg (55% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 81%, tR ) 6.38 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.87 (dd, J ) 14 Hz, J ) 7.6 Hz, 1H),
3.07 (dd, J ) 14.1 Hz, J ) 5.3 Hz, 1H), 3.71 (s, 3H), 4.94
(dd, J ) 14 Hz, J ) 7.6 Hz, 1H), 6.13 (d, J ) 7.4 Hz, 1H),
6.63 (d, J ) 8.2 Hz, 2H), 7.12 - 7.27 (m, 15H), 7.50 (d, J
) 8.2 Hz, 2H); LC/MS calcd for C30H26INO3 [M + H]
+
576.1; found 576.1.
Methyl 2-Methoxy-N-(triphenylacetyl)phenylalaninate
[8{23}a]: 3.9 mg (8% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 8:92 to 15:85) of
pooled duplicate samples; initial LC/MS purity 24%-25%,
tR ) 6.07 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ
2.91-3.12 (m, 2H), 3.43 (s, 3H), 3.72 (s, 3H), 4.75-4.85
(m, 1H), 6.59 (d, J ) 6.6 Hz, 1H), 6.72-7.10 (m, 4H),
7.11-7.29 (m,15H); LC/MS calcd for C31H29NO4 [M + H]
+
480.2; found 480.2.
Methyl 3-Methoxy-N-(triphenylacetyl)phenylalaninate
[8{24}a]: 12.0 mg (25% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 8:92 to 15:85) of
pooled duplicate samples; initial LC/MS purity 37%-38%,
tR ) 5.97 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ
2.88 (dd, J ) 13.9 Hz, J ) 8.1 Hz, 1H), 3.12 (dd, J ) 14.1
Hz, J ) 5.3 Hz, 1H), 3.69 (s, 3H), 3.72 (s,3H), 4.87-4.97
(m, 1H), 6.17 (d, J ) 7.2 Hz, 1H), 6.45-6.78 (m, 4H),
7.06-7.29 (m,15H). LC/MS calcd for C31H29NO4 [M + H]
+
480.2; found 480.2.
Methyl O-Methyl-N-(triphenylacetyl)tyrosinate [8{25}a]:
12.0 mg (25% isolated yield) following chromatographic
puriﬁcation (EtOAc/hexanes, 8:92 to 15:85) of pooled
duplicate samples; initial LC/MS purity 38%-46%, tR ) 5.94
min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.86 (dd,
J ) 14.2 Hz, J ) 7.6 Hz, 1H), 3.05 (dd, J ) 14.1 Hz, J )
5.1 Hz, 1H), 3.71 (s, 3H), 3.78 (s, 3H), 4.85-4.96 (m, 1H),
6.15 (d, J ) 7.6 Hz, 1H), 6.68-6.82 (m, 4H), 7.12-7.26
(m,15H); LC/MS calcd for C31H29NO4 [M + H]
+ 480.2;
found 480.2.
Methyl 4-Methyl-N-(triphenylacetyl)phenylalaninate
[8{26}a]: 14.7 mg (64% isolated yield) following chromato-
graphic puriﬁcation (EtOAc/hexanes, 15:85); initial LC/MS
purity 97%, tR ) 6.21 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.31 (s, 3H), 2.87 (dd, J ) 14.0 Hz, J )
7.6 Hz, 1H), 3.07 (dd, J ) 14.0 Hz, J ) 5.0 Hz, 1H), 3.71
(s, 3H), 4.86-4.96 (m, 1H), 6.15 (d, J ) 7.2 Hz, 1H), 6.76
(d, J ) 7.8 Hz, 2H), 6.99 (d, J ) 7.8 Hz, 2H), 7.12-7.25
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+ 464.2;
found 464.2.
Methyl r-[(Triphenylacetyl)amino]-1-naphthalenepro-
panoate [8{27}a]: 8.8 mg (35% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 15:85); initial
LC/MS purity 64%, tR ) 6.31 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.26-3.74 (m, 2H), 3.67 (s, 3H),
5.02 (dd, J ) 15.0 Hz, J ) 7.0 Hz, 1H), 6.23 (d, J ) 6.8
Hz, 1H), 6.95-7.51 (m, 19H), 7.80 (m, 2H), 8.00 (d, J )
7.6 Hz, 1H); LC/MS calcd for C30H26BrNO3 [M + H]
+
500.2; found 500.2.
Methyl r-[(Triphenylacetyl)amino]-2-naphthalenepro-
panoate [8{28}a]: 17.7 mg (71% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 15:85); initial
LC/MS purity 88%, tR ) 6.32 min;
1H NMR (200 MHz,
10% CD3OD/CDCl3) δ 3.05 (dd, J ) 14.1 Hz, J ) 8.1 Hz,
1H), 3.33 (dd, J ) 13.9 Hz, J ) 5.1 Hz, 1H), 3.74 (s, 3H),
4.97-5.07 (m, 1H), 6.17 (d, J ) 7.0 Hz, 1H), 7.07-7.33
(m, 15H), 7.44-7.83 (m, 7H); LC/MS calcd for C34H29NO3
[M + H]
+ 500.2; found 500.2.
b ) Series: 8, R2 ) N-(1-Oxo-3,3,3-triphenylpropyl)
) N-(Triphenylpropionyl). Methyl N-(1-Oxo-3,3,3-triph-
enylpropyl)phenylalaninate [8{9}b]: 18.3 mg (79% isolated
yield) following chromatographic puriﬁcation (CH2Cl2/
EtOAc/hexanes, 10:15:75 to 20:20:60) of pooled duplicate
samples; initial LC/MS purity 86, 87%, tR ) 5.92 min;
1H
NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.74-2.78 (m, 2H),
3.52 (d, J ) 15.0 Hz, 1H), 3.56 (s, 3H), 3.66 (d, J ) 15.0
Hz, 1H), 4.59 (dd, J ) 14 Hz, J ) 6.2 Hz, 1H), 5.40 (d, J
) 7.4 Hz, 1H), 6.82-6.87 (m, 2H), 7.18-7.29 (m, 18H);
LC/MS calcd for C31H29NO3 [M + H]
+ 464.2; found 464.2.
Methyl 2-Fluoro-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{10}b]: 12.6 mg (52% isolated yield)
following chromatographic puriﬁcation (EtOAc/hexanes,
8:92 to 15:85); initial LC/MS purity 83%, tR ) 5.91 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.79-2.84
(m, 2H), 3.57 (d, J ) 14.8 Hz, 1H), 3.58 (s, 3H), 3.63 (d,
J ) 14.8 Hz, 1H), 4.56 (dd, J ) 13.5 Hz, J ) 6.4 Hz,
1H), 5.44 (d, J ) 7.0 Hz, 1H), 6.85-7.26 (m, 19H); LC/
MS calcd for C31H28FNO3 [M + H]
+ 482.2; found 482.2.
Methyl 3-Fluoro-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{11}b]: 7.7 mg (32% isolated yield) fol-
lowing chromatographic puriﬁcation (EtOAc/hexanes, 8:92
to 15:85); initial LC/MS purity 70%, tR ) 5.95 min;
1H
NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.73-2.79 (m,
2H), 3.54 (d, J ) 15.2 Hz, 1H), 3.58 (s, 3H), 3.67 (d, J
) 15.2 Hz, 1H), 4.60 (dd, J ) 13.4 Hz, J ) 6.2 Hz, 1H),
5.40 (d, J ) 7.0 Hz, 1H), 6.54-6.93 (m, 3H), 7.09-7.30
(m, 16H); LC/MS: calcd for C31H28FNO3 [M + H]
+ 482.2;
found 482.2.
Methyl 4-Fluoro-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{12}b]: 18.1 mg (75% isolated yield)
following chromatographic puriﬁcation (EtOAc/hexanes,
8:92 to 15:85); initial LC/MS purity 83%, tR ) 5.93 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.71-2.76
(m, 2H), 3.53 (d, J ) 14.6 Hz, 1H), 3.57 (s, 3H), 3.67 (d,
J ) 14.6 Hz, 1H), 4.58 (dd, J ) 13.4 Hz, J ) 6.0 Hz,
1H), 5.39 (d, J ) 7.2 Hz, 1H), 6.75-6.92 (m, 4H),
7.16-7.30 (m, 15H); LC/MS: calcd for C31H28FNO3 [M
+ H]
+ 482.2; found 482.2.
Methyl 2-(Triﬂuoromethyl)-N-(1-oxo-3,3,3-triphenyl-
propyl)phenylalaninate [8{13}b]: 16.6 mg (63% isolated
yield) following chromatographic puriﬁcation (EtOAc/
hexanes, 8:92); initial LC/MS purity 89%, tR ) 6.13 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.66-2.93
(m, 2H), 3.51 (d, J ) 15.0 Hz, 1H), 3.52 (s, 3H), 3.66 (d,
J ) 15.2 Hz, 1H), 4.60 (dd, J ) 15.0 Hz, J ) 7.6 Hz,
1H), 5.41 (d, J ) 7.6 Hz, 1H), 7.12-7.43 (m, 18H), 7.59
(d, J ) 7.2 Hz, 1H); LC/MS calcd for C32H29F3NO3 [M
+ H]
+ 532.2; found 532.2.
Methyl 3-(Triﬂuoromethyl)-N-(1-oxo-3,3,3-triphenyl-
propyl)phenylalaninate [8{14}b]: 5.7 mg (22% isolated
yield) following chromatographic puriﬁcation (EtOAc/
hexanes, 8:92); initial LC/MS purity 72%, tR ) 6.21 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.70-2.91
(m, 2H), 3.54 (d, J ) 14.8 Hz, 1H), 3.56 (s, 3H), 3.66 (d,
J ) 15.0 Hz, 1H), 4.61 (dd, J ) 13.3 Hz, J ) 6.3 Hz,
1H), 5.39 (d, J ) 7.2 Hz, 1H), 7.05 (d, J ) 7.6 Hz, 1H),
7.14-7.35 (m, 17H), 7.47 (d, J ) 7.6 Hz, 1H); LC/MS
calcd for C32H29F3NO3 [M + H]
+ 532.2; found 532.2.
Methyl 4-(Triﬂuoromethyl)-N-(1-oxo-3,3,3-triphenyl-
propyl)phenylalaninate [8{15}b]: 18.5 mg (70% isolated
yield) following chromatographic puriﬁcation (EtOAc/hex-
anes in CH2Cl2, 4:46:50); initial LC/MS purity 80%, tR )
6.22 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ
2.70-2.97 (m, 2H), 3.54 (d, J ) 15.0 Hz, 1H), 3.58 (s, 3H),
3.68 (d, J ) 15.0 Hz, 1H), 4.64 (dd, J ) 13.4 Hz, J ) 6.0
Hz, 1H), 5.39 (d, J ) 7.4 Hz, 1H), 6.95 (d, J ) 8.0 Hz,
2H), 7.10-7.35 (m, 15H), 7.43 (d, J ) 8.0 Hz, 2H); LC/
MS calcd for C32H29F3NO3 [M + H]
+ 532.2; found 532.2.
Methyl 2-Bromo-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{16}b]: 8.8 mg (33% isolated yield) fol-
lowing chromatographic puriﬁcation (EtOAc/hexanes,
8:92); initial LC/MS purity 94%, tR ) 6.11 min;
1H NMR
(200 MHz, 10% CD3OD/CDCl3) δ 2.77 (dd, J ) 14.1 Hz,
J ) 7.5 Hz, 1H), 2.92 (dd, J ) 14.1 Hz, J ) 6.7 Hz, 1H),
3.54 (d, J ) 14.8 Hz, 1H), 3.57 (s, 3H), 3.63 (d, J ) 14.8
Hz, 1H), 4.60 (dd, J ) 14.5 Hz, J ) 7.3 Hz, 1H), 5.39
(d, J ) 7.2 Hz, 1H), 6.93 (d, J ) 7.0 Hz, 1H), 7.00-7.30
(m, 17H), 7.50 (d, J ) 7.8 Hz, 1H); LC/MS: calcd for
C31H29BrNO3 [M + H]
+ 542.1; found 542.2.
Methyl 3-Bromo-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{17}b]: 8.5 mg (31% isolated yield) follow-
ing chromatographic puriﬁcation (EtOAc/hexanes, 8:92);
initial LC/MS purity 84%, tR ) 6.21 min;
1H NMR (200
MHz, 10% CD3OD/CDCl3) δ 2.60-2.85 (m, 2H), 3.54 (d,
J ) 15.2 Hz, 1H), 3.58 (s, 3H), 3.67 (d, J ) 15.2 Hz, 1H),
4.59 (dd, J ) 13.3 Hz, J ) 6.3 Hz, 1H), 5.38 (d, J ) 7.2
Hz, 1H), 6.79 (d, J ) 7.8 Hz, 1H), 6.95-7.40 (m, 18H);
LC/MS calcd for C31H29BrNO3 [M + H]
+ 542.1; found
542.2.
Methyl 4-Bromo-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{18}b]: 12.9 mg (48% isolated yield) fol-
lowing chromatographic puriﬁcation (EtOAc/hexanes in
CH2Cl2, 4:46:50); initial LC/MS purity 87%, tR ) 6.23 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.60-2.90 (m,
2H), 3.53 (d, J ) 15.0 Hz, 1H), 3.57 (s, 3H), 3.67 (d, J )
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(d, J ) 7.4 Hz, 1H), 6.70 (d, J ) 8.4 Hz, 2H), 7.10-7.38
(m, 17H); LC/MS calcd for C31H29BrNO3 [M + H]
+ 542.1;
found 542.2.
Methyl 3-Cyano-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{19}b]: 7.5 mg (31% isolated yield) follow-
ing chromatographic puriﬁcation (EtOAc/hexanes, 8:92 to
15:85); initial LC/MS purity 78%, tR ) 5.67 min;
1HN M R
(200 MHz, 10% CD3OD/CDCl3) δ 2.62-2.91 (m, 2H), 3.55
(d, J ) 15.2 Hz, 1H), 3.58 (s, 3H), 3.67 (d, J ) 15.2 Hz,
1H), 4.62 (dd, J ) 12.9 Hz, J ) 6.1 Hz, 1H), 5.42 (d, J )
7.2 Hz, 1H), 7.05-7.39 (m, 18H), 7.50 (d, J ) 7.8 Hz, 1H);
LC/MS calcd for C32H29N2O3 [M + H]
+ 489.2; found 489.2.
Methyl 4-Cyano-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{20}b]: 19.1 mg (78% isolated yield)
following chromatographic puriﬁcation (EtOAc/hexanes,
8:92 to 15:85); initial LC/MS purity 76%, tR ) 5.65 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 2.77 (dd, J
) 13.9 Hz, J ) 6.1 Hz, 1H), 2.87 (dd, J ) 13.9 Hz, J )
6.1 Hz, 1H), 3.54 (d, J ) 15.0 Hz, 1H), 3.57 (s, 3H),
3.68 (d, J ) 15.0 Hz, 1H), 4.63 (dd, J ) 13.3 Hz, J )
6.3 Hz, 1H), 5.41 (d, J ) 7.4 Hz, 1H), 6.96 (d, J ) 8.4
Hz, 2H), 7.10-7.38 (m, 15H), 7.46 (d, J ) 8.4 Hz, 2H);
LC/MS calcd for C32H29N2O3 [M + H]
+: 489.2; found
489.3.
Methyl 2-Iodo-N-(1-oxo-3,3,3-triphenylpropyl)pheny-
lalaninate [8{21}b]: 18.9 mg (64% isolated yield) follow-
ing chromatographic puriﬁcation (EtOAc/hexanes, 8:92);
initial LC/MS purity 86%, tR ) 6.18 min;
1H NMR (200
MHz, 10% CD3OD/CDCl3) δ 2.74 (dd, J ) 14.2 Hz, J )
7.6 Hz, 1H), 2.89 (dd, J ) 14.1 Hz, J ) 6.9 Hz, 1H),
3.54 (d, J ) 15.2 Hz, 1H), 3.57 (s, 3H), 3.64 (d, J ) 15.2
Hz, 1H), 4.60 (dd, J ) 14.7, Hz, J ) 7.3 Hz, 1H), 5.37
(d, J ) 7.2 Hz, 1H), 6.92 (d, J ) 7.6 Hz, 2H), 7.08-7.40
(m, 16H), 7.78 (d, J ) 7.8 Hz, 1H); LC/MS calcd for
C31H29INO3 [M + H]
+ 590.1; found 590.1.
Methyl 4-Iodo-N-(1-oxo-3,3,3-triphenylpropyl)pheny-
lalaninate [8{22}b]: 19.6 mg (67% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes in CH2Cl2,
4:46:50); initial LC/MS purity 81%, tR ) 6.31 min;
1H NMR
(200 MHz, 10% CD3OD/CDCl3) δ 2.59-2.82 (m, 2H), 3.53
(d, J ) 15.2 Hz, 1H), 3.57 (s, 3H), 3.67 (d, J ) 15.2 Hz,
1H), 4.59 (dd, J ) 13.4 Hz, J ) 6.0 Hz, 1H), 5.38 (d, J )
7.4 Hz, 1H), 6.58 (d, J ) 8.2 Hz, 2H), 7.10-7.32 (m, 15H),
7.49 (d, J ) 8.2 Hz, 2H); LC/MS calcd for C31H29INO3 [M
+ H]
+ 590.1; found 590.1.
Methyl 2-Methoxy-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{23}b]: 4.3 mg (9% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 8:92 to 15:
85) of pooled duplicate samples; initial LC/MS purity
40%-42%, tR ) 5.96 min;
1H NMR (200 MHz, 10%
CD3OD/CDCl3) δ 2.73-2.76 (m, 2H), 3.43 (d, J ) 15.0 Hz,
1H), 3.56 (s, 3H), 3.63 (d, J ) 15.0 Hz, 1H), 3.73 (s, 3H),
4.47 (dd, J ) 13.6 Hz, J ) 6.8 Hz, 1H), 5.58 (d, J ) 6.6
Hz, 1H), 6.79-6.81 (m, 3H), 7.14-7.26 (m, 16H); LC/MS
calcd for C32H31NO4 [M + H]
+ 494.2; found 494.3.
Methyl 3-Methoxy-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{24}b]: 4.3 mg (17% isolated yield) follow-
ing chromatographic puriﬁcation (EtOAc/hexanes, 8:92 to
15:85); initial LC/MS purity 61%, tR ) 5.90 min;
1HN M R
(200 MHz, 10% CD3OD/CDCl3) δ 2.70-2.75 (m, 2H), 3.53
(d, J ) 15.2 Hz, 1H), 3.57 (s, 3H), 3.65 (d, J ) 15.2 Hz,
1H), 3.74 (s, 3H), 4.58 (dd, J ) 14.0 Hz, J ) 6.2 Hz, 1H),
5.39 (d, J ) 7.4 Hz, 1H), 6.41-6.45 (m, 2H), 6.73-6.76
(m, 1H), 7.06-7.63 (m, 16H); LC/MS calcd for C31H29NO3
[M + H]
+ 494.2; found 494.3.
Methyl O-Methyl-N-(1-oxo-3,3,3-triphenylpropyl)tyro-
sinate [8{25}b]: 4.0 mg (16% isolated yield) following
chromatographic puriﬁcation (EtOAc/hexanes, 8:92 to 15:
85); initial LC/MS purity 57%, tR ) 5.86 min;
1H NMR
(200 MHz, 10% CD3OD/CDCl3) δ 2.69-2.71 (m, 2H),
3.52 (d, J ) 15.2 Hz, 1H), 3.57 (s, 3H), 3.66 (d, J ) 15.2
Hz, 1H), 3.77 (s, 3H), 4.55 (dd, J ) 13.4 Hz, J ) 6.2 Hz,
1H), 5.38 (d, J ) 7.4 Hz, 1H), 6.74 (m, 4H), 7.18-7.26
(m, 15H); LC/MS: calcd for C31H29NO3 [M + H]
+ 494.2;
found 494.3.
Methyl 4-Methyl-N-(1-oxo-3,3,3-triphenylpropyl)phe-
nylalaninate [8{26}b]: 9.5 mg (40% isolated yield) follow-
ing chromatographic puriﬁcation (EtOAc/hexanes, 8:92);
initial LC/MS purity 100%, tR ) 6.12 min;
1H NMR (200
MHz, 10% CD3OD/CDCl3) δ 2.30 (s, 3H), 2.60-2.81 (m,
2H), 3.52 (d, J ) 15.2 Hz, 1H), 3.57 (s, 3H), 3.65 (d, J )
15.2 Hz, 1H), 4.56 (dd, J ) 13.2 Hz, J ) 6.2 Hz, 1H), 5.39
(d, J ) 7.6 Hz, 1H), 6.73 (d, J ) 7.8 Hz, 2H), 6.99 (d, J )
7.8 Hz, 2H), 7.10-7.32 (m, 15H); LC/MS calcd for
C32H32NO3 [M + H]
+ 478.2; found 478.3.
Methyl r-[(1-Oxo-3,3,3-triphenylpropyl)amino]-1-naph-
thalenepropanoate [8{27}b]: 5.0 mg (20% isolated yield)
following chromatographic puriﬁcation (EtOAc/hexanes in
CH2Cl2, 4:46:50); initial LC/MS purity 80%, tR ) 6.23 min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ 3.03-3.31 (m,
2H), 3.45 (s, 3H), 3.57 (s, 2H), 4.68 (dd, J ) 14.0 Hz, J )
7.0 Hz, 1H), 5.43 (d, J ) 7.0 Hz, 1H), 6.94 (d, J ) 6.8 Hz,
1H), 7.07-8.00 (m, 21H); LC/MS calcd for C35H32NO3 [M
+ H]
+ 514.2; found 514.3.
Methyl r-[(1-Oxo-3,3,3-triphenylpropyl)amino]-2-naph-
thalenepropanoate [8{28}b]: 14.7 mg (57% isolated yield)
following chromatographic puriﬁcation (EtOAc/hexanes
in CH2Cl2, 4:46:50); initial LC/MS purity 87%, tR ) 6.26
min;
1H NMR (200 MHz, 10% CD3OD/CDCl3) δ
2.80-3.21 (m, 2H), 3.52 (d, J ) 15.2 Hz, 1H), 3.56 (s,
3H), 3.66 (d, J ) 15.2 Hz, 1H), 4.71 (dd, J ) 13.4 Hz, J
) 6.2 Hz, 1H), 5.39 (d, J ) 7.4 Hz, 1H), 7.00 (d, J ) 6.8
Hz, 1H), 7.02 - 7.82 (m, 21H); LC/MS calcd for
C35H32NO3 [M + H]
+ 514.2; found 514.3.
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